Bone defects due to disease or trauma affect millions of people worldwide. In recent years, bone tissue engineering, combining biomaterials, cells and growth factors, has emerged as a promising therapeutic approach to treat large bone defects. Multipotent mesenchymal stem cells isolated from adipose tissue are an attractive option for bone tissue engineering application in comparison with, for example, bone marrow-derived stem cells (BMSCs). Human adipose stem cells (hASCs) are readily available in substantial amounts and can be differentiated into bone-forming cells. Human ASCs have already been used in clinical bone tissue engineering in combination with biomaterials and growth factors. However, there is a need for more cost-effective approaches to induce osteogenic differentiation of hASCs.